Home > Authorities > Periodicals > Cancer biology & medicine > print

001     146907
005     20231027183232.0
022 _ _ |a 2095-3941
022 _ _ |a 2095-3941
|l 2095-3941
024 7 _ |2 ZDBID
|a PERI:(DE-600)2676322-9
024 7 _ |2 ZDBPPN
|a ZDPPN:1024875466
024 7 _ |2 EZBID
|a PERI:(DE-606)186143
024 7 _ |2 OCLC
|a OCLC:812213198
024 7 _ |2 JCR
|a JCR:CANCER BIOL MED
024 7 _ |2 ISI
|a WOS:CANCER BIOLOGY & MEDICINE
024 7 _ |2 SCOPUS
|a SCOPUS:21100237607
024 7 _ |2 Medline
|a medline:101588850
035 _ _ |a PERI:(DE-600)2676322-9
040 _ _ |a 4002
|b ger
|c DE-101
|d JOIN²
|e JOIN² journal identification
041 _ _ |a eng
044 _ _ |c XB-CN
082 _ _ |2 22sdnb
|a 610
|q DE-600
082 7 4 |2 22sdnb
|a 610
|q DE-600
084 _ _ |2 fid
|a ASIEN
|q DE-1a
210 0 _ |2 DE-600
|a Cancer Biol Med
210 0 _ |2 dnlm
|a Cancer Biol Med
210 0 _ |2 iso
|a Cancer Biol Med
242 2 0 |2 DE-600
|a Cancer biology & medicine
|c Zhong guo kang ai xie hui
|y en
242 2 0 |2 DE-600
|6 246-01/Hans
|a 癌症生物学与医学
|i Paralleltitel
|y Hans
242 2 0 |2 DE-600
|a Cancer biology & medicine
|c Zhong guo kang ai xie hui
245 _ _ |2 DE-600
|a Cancer biology & medicine
|c Zhong guo kang ai xie hui
|h online, print
246 3 _ |2 DE-600
|a Cancer biology & medicine
246 3 _ |a Cancer biology & medicine
246 3 _ |a Clinical oncology and cancer research
260 _ _ |a Tianjin
|b Medical Univ. Cancer Inst. & Hospital
|c 2012-
260 7 _ |2 DOAJ
|a China
|b China Anti-Cancer Association
|d 2019-02-25T09:25:10Z
264 3 1 |a Tianjin
|b Medical Univ. Cancer Inst. & Hospital
|c 2012-
362 0 _ |2 DE-600
|a 9.2012 -
363 0 1 |2 DE-600
|8 1.1\x
|a 9
|i 2012
365 _ _ |2 DOAJ
|a APC
|b 1500
|c USD
|d 2019-02-25T09:25:10Z
380 _ _ |2 marcgt
|a journal
500 _ _ |a Automatically generated record. (Updated: 2023-10-26)
540 _ _ |5 PubMed Central
|a Immediate free access, All OpenAccess, Full coverage
|d 2023-10-26
650 _ 7 |0 ASJC:1306
|2 ASJC
|a Cancer Research
650 _ 7 |0 ASJC:2730
|2 ASJC
|a Oncology
653 1 0 |2 EZB-Subject
|a Biologie, Biotechnologie
653 1 0 |2 EZB-Subject
|a Medizin
653 1 0 |2 EZB-Keyword
|a Biomedizin,Onkologie
653 1 0 |2 DOAJ
|a cancer genetics
|d 2019-02-25T09:25:10Z
653 1 0 |2 DOAJ
|a oncology clinical trials
|d 2019-02-25T09:25:10Z
653 1 0 |2 DOAJ
|a targeted therapy and immunology
|d 2019-02-25T09:25:10Z
653 1 0 |2 DOAJ
|a cancer and stem cell biology
|d 2019-02-25T09:25:10Z
653 1 0 |2 DOAJ
|a cancer prevention and epidemiology
|d 2019-02-25T09:25:10Z
653 1 0 |2 DOAJ
|a cancer biomarkers
|d 2019-02-25T09:25:10Z
653 1 0 |2 DOAJ
|a Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
|d 2019-02-25T09:25:10Z
776 0 8 |2 DE-600
|i Erscheint auch als
|n Druck-Ausgabe
|t Cancer biology & medicine
|x 2095-3941
780 0 0 |2 DE-600
|d Beijing : Springer, 2009-2011
|h Online-Ressource
|i Vorg.:
|t Clinical oncology and cancer research
|w (DE-600)2594620-1
|x 1868-324X
856 4 _ |d 0
|u http://erf.sbb.spk-berlin.de/han/caj/oversea.cnki.net/knavi/JournalDetail?pcode=CJFD&pykm=CJCO
|y Verlag; CrossAsia Link = Deutschlandweit zugänglich
856 4 _ |d 0
|u http://ezb.uni-regensburg.de/2676322
|y EZB
856 4 _ |d 0
|u http://www.cancerbiomed.org/index.php/cocr/about/editorialPolicies#focusAndScope
|y Scope
856 4 _ |d 0
|u http://www.cancerbiomed.org/index.php/cocr/about/editorialPolicies#peerReviewProcess
|y Review process
856 4 _ |d 0
|u http://www.cancerbiomed.org/index.php/cocr/about/editorialTeam
|y Editorial board
856 4 _ |d 0
|u http://www.cancerbiomed.org/index.php/cocr/pages/view/instructions_authors
|y Instructions for Authors
856 4 _ |d 0
|u http://www.cancerbiomed.org/index.php/cocr/pages/view/instructions_authors#charges_
|y APC information
856 4 _ |d 0
|u https://oversea.cnki.net/knavi/JournalDetail?pcode=CJFD&pykm=CJCO
|y Verlag = Deutschlandweit zugänglich
856 4 _ |d 0
|u https://www.cancerbiomed.org/content/by/year
|y Verlag = kostenfrei
856 4 _ |d 0
|u https://www.ncbi.nlm.nih.gov/pmc/journals/2000
|y Verlag = kostenfrei
880 _ _ |2 DE-600
|6 246-01/Hans
|a 癌症生物学与医学
|i Paralleltitel
880 1 _ |2 DE-600
|a Cancer biology & medicine
|c Zhong guo kang ai xie hui
909 C O |o oai:juser.fz-juelich.de:132531
|p authority:PERI
|p authority
909 C O |o oai:juser.fz-juelich.de:132531
915 _ _ |0 StatID:(DE-HGF)0420
|2 StatID
|a Nationallizenz
|d 2023-10-26
|w ger
915 _ _ |0 StatID:(DE-HGF)0100
|2 StatID
|a JCR
|b CANCER BIOL MED : 2022
|d 2023-10-26
915 _ _ |0 StatID:(DE-HGF)0200
|2 StatID
|a DBCoverage
|b SCOPUS
|d 2023-10-26
915 _ _ |0 StatID:(DE-HGF)0300
|2 StatID
|a DBCoverage
|b Medline
|d 2023-10-26
915 _ _ |0 StatID:(DE-HGF)0320
|2 StatID
|a DBCoverage
|b PubMed Central
|d 2023-10-26
915 _ _ |0 StatID:(DE-HGF)0501
|2 StatID
|a DBCoverage
|b DOAJ Seal
|d 2019-02-25T09:25:10Z
915 _ _ |0 StatID:(DE-HGF)0500
|2 StatID
|a DBCoverage
|b DOAJ
|d 2019-02-25T09:25:10Z
915 _ _ |0 StatID:(DE-HGF)0030
|2 StatID
|a Peer Review
|b DOAJ : Anonymous peer review
|d 2019-02-25T09:25:10Z
915 _ _ |0 LIC:(DE-HGF)CCBYNCNV
|2 V:(DE-HGF)
|a Creative Commons Attribution-NonCommercial CC BY-NC (No Version)
|b DOAJ
|d 2019-02-25T09:25:10Z
915 _ _ |0 StatID:(DE-HGF)0600
|2 StatID
|a DBCoverage
|b Ebsco Academic Search
|d 2023-10-26
915 _ _ |0 StatID:(DE-HGF)0030
|2 StatID
|a Peer Review
|b ASC
|d 2023-10-26
915 _ _ |0 StatID:(DE-HGF)0199
|2 StatID
|a DBCoverage
|b Clarivate Analytics Master Journal List
|d 2023-10-26
915 _ _ |0 StatID:(DE-HGF)1050
|2 StatID
|a DBCoverage
|b BIOSIS Previews
|d 2023-10-26
915 _ _ |0 StatID:(DE-HGF)0113
|2 StatID
|a WoS
|b Science Citation Index Expanded
|d 2023-10-26
915 _ _ |0 StatID:(DE-HGF)0150
|2 StatID
|a DBCoverage
|b Web of Science Core Collection
|d 2023-10-26
915 _ _ |0 StatID:(DE-HGF)1190
|2 StatID
|a DBCoverage
|b Biological Abstracts
|d 2023-10-26
915 _ _ |0 StatID:(DE-HGF)0160
|2 StatID
|a DBCoverage
|b Essential Science Indicators
|d 2023-10-26
915 _ _ |0 StatID:(DE-HGF)9905
|2 StatID
|a IF >= 5
|b CANCER BIOL MED : 2022
|d 2023-10-26
915 _ _ |0 StatID:(DE-HGF)0561
|2 StatID
|a Article Processing Charges
|d 2023-10-26
915 _ _ |0 StatID:(DE-HGF)0700
|2 StatID
|a Fees
|d 2023-10-26
936 _ _ |a Vorgänger: Clinical oncology and cancer research
980 _ _ |a PERI
980 _ _ |a AUTHORITY

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21